Quest Diagnostics, Inc.

NYSE:DGX  
146.55
+1.19 (+0.82%)
4:00:00 PM EDT: $146.58 +0.03 (+0.02%)
Other Pre-Announcement

Zora Biosciences Licenses Ceramide Technology To Quest Diagnostics For Cardiovascular Mortality Prediction Test

Published: 03/15/2021 13:24 GMT
Quest Diagnostics, Inc. (DGX) - Zora Biosciences Licenses Ceramide Technology to Quest Diagnostics for Cardiovascular Mortality Prediction Test.
Quest - Expects to Begin to Offer New Test Service in U.S. Through Its Cardiometabolic Center of Excellence at Cleveland Heartlab As Soon As Next Year.
Quest -plans to Develop Test Service Based on Zora's Ceramide Tech As an Aid in Identifying Patients at Risk for Cardiovascular-related Disease, Death.